Management of Superficial Thrombophlebitis

Diagnostic Approach

Ultrasound imaging is essential to confirm the diagnosis and exclude subclinical deep vein thrombosis (DVT), as approximately 25% of patients with superficial thrombophlebitis have underlying DVT 2
Compression ultrasound should be used to determine the extent and proximity to deep veins 3

The American College of Cardiology recommends prophylactic-dose fondaparinux 2.5 mg daily for 45 days (Grade 2B) for extensive superficial thrombophlebitis 1, 2
Alternative: Prophylactic-dose low-molecular-weight heparin (LMWH) for 45 days if fondaparinux is unavailable (Grade 2C) 4, 2
Anticoagulation reduces the risk of progression to deep vein thrombosis (from 1.3% to 0.2%) and recurrent superficial vein thrombosis (from 1.6% to 0.3%) 5
For pregnant patients with superficial thrombophlebitis, LMWH is recommended over no anticoagulation (conditional recommendation) 5
Fondaparinux should be avoided during pregnancy as it crosses the placenta 5
Treatment should continue for the remainder of pregnancy and 6 weeks postpartum 6

Superficial thrombosis of the cephalic and basilic veins generally does not require anticoagulant therapy 2
If associated with a central venous catheter, consider catheter removal if no longer functional 2
Active cancer is a risk factor for progression 4
Length >5 cm is a risk factor for progression 1

Failure to perform ultrasound to exclude concurrent DVT 2
Inadequate duration of anticoagulation (45 days is recommended for extensive disease) 1